| Items 101 ~ 120 of 25944, Page 6 of 1298 |
| 101. |
Statement on steps toward a new, tailored review framework for artificial intelligence-based medical devices - 04/02/2019
U.S. FOOD & DRUG ADMINISTRATION |
| 102. |
Bariatric Embolization Shows Promise in Treatment of Obesity - 04/02/2019
Radiological Society of North America |
| |
Bariatric embolization, a new, minimally invasive treatment for obesity produces weight loss and reduces appetite for up to one year, according to a new study published in the journal Radiology. |
| 103. |
Older Women Benefit Significantly When Screened with 3-D Mammography - 04/02/2019
Radiological Society of North America |
| |
Mammography remains an effective method for breast cancer screening in women ages 65 and older, with the addition of a 3-D technique called tomosynthesis improving screening performances even more, according to a study published in the journal Radiology. |
| 104. |
Statement from FDA Commissioner Scott Gottlieb, M.D., on the agency¡¯s continued efforts to bring competition to the insulin market to lower prices and expand access - 04/02/2019
U.S. FOOD & DRUG ADMINISTRATION |
| 105. |
FDA takes new enforcement actions as part of the agency¡¯s ongoing effort to combat the illegal online sales of opioids - 04/02/2019
U.S. FOOD & DRUG ADMINISTRATION |
| 106. |
Statement on new steps to advance agency¡¯s continued evaluation of potential regulatory pathways for cannabis-containing and cannabis-derived products - 04/02/2019
U.S. FOOD & DRUG ADMINISTRATION |
| 107. |
Merck Completes Tender Offer to Acquire Immune Design - 04/02/2019
MERCK |
| 108. |
USDA, EPA, and FDA Recognize April as Winning on Reducing Food Waste Month - 04/02/2019
U.S. FOOD & DRUG ADMINISTRATION |
| 109. |
Merck to Hold First-Quarter 2019 Sales and Earnings Conference Call on April 30 - 04/02/2019
MERCK |
| 110. |
Selumetinib Granted U.S. Breakthrough Therapy Designation in Neurofibromatosis Type 1 - 04/01/2019
MERCK |
| |
Designation Based on Phase 2 SPRINT Trial in Pediatric Patients with NF1 Plexiform Neurofibromas / Selumetinib Is a MEK 1/2 Inhibitor Being Co-Developed by AstraZeneca and Merck |
| 111. |
Merck Completes Acquisition of Antelliq Corporation to Become Leader in Emerging Digital Technology for Livestock and Companion Animals - 04/01/2019
MERCK |
| 112. |
Statement on new efforts to advance treatment strategies for helping youth addicted to nicotine as a result of the epidemic rise in teen use of e-cigarettes - 04/01/2019
U.S. FOOD & DRUG ADMINISTRATION |
| 113. |
FDA warns homeopathic firms for putting patients at risk with significant violations of manufacturing quality standards - 04/01/2019
U.S. FOOD & DRUG ADMINISTRATION |
| 114. |
Merck¡¯s KEYTRUDA¢ç (pembrolizumab) Approved in China for First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC) in Combination with Chemotherapy - 04/01/2019
MERCK |
| |
KEYTRUDA is First Anti-PD-1 Therapy to be Approved in Multiple Tumor Types in China |
| 115. |
Data for Merck¡¯s KEYTRUDA¢ç (pembrolizumab) Across Different Types of Advanced Lung Cancer Presented at AACR Annual Meeting 2019 - 04/01/2019
MERCK |
| |
First Presentation of Overall Survival Data from Post-Hoc Analysis of KEYNOTE-189 in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Who Have Liver or Brain Metastases / Pooled Data in Patients with Previously Treated Advanced Small Cell Lung Cancer in AACR 2019 Plenary Session and Press Conference |
| 116. |
FDA approves new oral treatment for multiple sclerosis - 03/29/2019
U.S. FOOD & DRUG ADMINISTRATION |
| 117. |
Statement by FDA Commissioner Scott Gottlieb, M.D., Director of FDA¡¯s Center for Drug Evaluation and Research Janet Woodcock, M.D. and Director of FDA¡¯s Center for Biologics Evaluation and Research Peter Marks, M.D. on Expanded Access ?Looking Forward - 03/29/2019
U.S. FOOD & DRUG ADMINISTRATION |
| 118. |
FDA approves treatment for patients with a type of inflammatory arthritis - 03/28/2019
U.S. FOOD & DRUG ADMINISTRATION |
| 119. |
Statement on actions to advance our comprehensive plan to reduce tobacco-related disease and death, through new efforts to improve the tobacco product application review process, including a newly proposed rule - 03/28/2019
U.S. FOOD & DRUG ADMINISTRATION |
| 120. |
Remarks from FDA Commissioner Scott Gottlieb, M.D., as prepared for testimony before a U.S. Senate Subcommittee on Appropriations on FDA¡¯s Fiscal Year 2020 budget - 03/28/2019
U.S. FOOD & DRUG ADMINISTRATION |
